Three-drug immunotherapy for melanoma brain metastases
Treatments studied
Part of Brain & nervous system, Cancer, Skin clinical trials.
This trial tests a combination of three immunotherapy drugs (relatlimab, nivolumab, and ipilimumab) for people with melanoma that has spread to the brain. It aims to see if this treatment can shrink brain tumors and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have melanoma (not from the eye) that has spread to the brain, with at least one brain tumor that hasn't been treated with radiation or surgery.
- You are 18 years or older and in generally good health (able to do light activities).
- You have not had immunotherapy for advanced melanoma before (like Opdivo, Yervoy, or relatlimab).
- You are not taking high doses of steroids for your brain symptoms, or you are on a stable low dose (no more than 4 mg of dexamethasone per day).
- You have a tumor tissue sample available for testing, or you are willing to have a biopsy.
- You are not pregnant or breastfeeding, and you agree to use effective birth control during and for 12 months after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a combination of three drugs (relatlimab, ipilimumab, and nivolumab) as a first treatment for advanced melanoma that cannot be removed by surgery. All participants will receive the drug combination, and the study will look at safety and how well it works.
This trial is testing a combination of two immunotherapy drugs (anti-LAG-3 and anti-PD-1 antibodies) to see if they work better than standard treatment for people with advanced melanoma that hasn't been treated before. It may be an option if you have not yet received any systemic therapy for your melanoma.
This trial tests a combination of two or three drugs (defactinib, avutometinib, with or without encorafenib) to shrink brain tumors that started from skin melanoma. It may be an option for people whose melanoma has a specific genetic change and who have already tried immunotherapy.
This trial tests a combination of three immunotherapy drugs (cemiplimab, fianlimab, and ipilimumab) before surgery in people with melanoma that can be surgically removed. The goal is to see if this treatment helps shrink the cancer and improves outcomes.
This trial tests if injecting two immunotherapy drugs (ipilimumab and nivolumab) just under the skin can help prevent high-risk stage II melanoma from spreading. It is for people who have recently had a thick melanoma removed and have not yet had a sentinel node biopsy.
This Phase 2 study tests whether nivolumab plus relatlimab can shrink or control melanoma that has spread to the brain. It may help by boosting the immune system to attack the cancer, including melanoma in brain areas that can’t be treated with prior focused radiation.
Hear when a new Melanoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.